<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Anesth Essays Res</journal-id><journal-id journal-id-type="iso-abbrev">Anesth Essays Res</journal-id><journal-id journal-id-type="publisher-id">AER</journal-id><journal-title-group><journal-title>Anesthesia, Essays and Researches</journal-title></journal-title-group><issn pub-type="ppub">0259-1162</issn><issn pub-type="epub">2229-7685</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25886103</article-id><article-id pub-id-type="pmc">4173581</article-id><article-id pub-id-type="publisher-id">AER-8-48</article-id><article-id pub-id-type="doi">10.4103/0259-1162.128908</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Emara</surname><given-names>Walid Mohamed</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Moez</surname><given-names>Khaled K.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Elkhouly</surname><given-names>Abeer H.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1">Department of Anesthesia, Faculty of Medicine, Tanta University, Tanta, Egypt</aff><aff id="aff2"><label>1</label>Department of Anesthesia, National Cancer Institute, Cairo University, Giza, Egypt</aff><author-notes><corresp id="cor1">
Corresponding author: Dr. Walid Mohamed Emara, Department of Anesthesia Faculty of Medicine, Tanta University, Tanta, Egypt. E-mail: <email xlink:href="walid64@yahoo.com">walid64@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Apr</season><year>2014</year></pub-date><volume>8</volume><issue>1</issue><fpage>48</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright: © Anesthesia: Essays and Researches</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="2978" xml_f="2989" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3000" xml_f="3317" txt_i="23" txt_f="340">This study was performed to test the effectiveness of topical tranexamic acid (TXA) in reducing blood loss in pelvic hemiarthoplasty surgeries compared with intravenous TXA, regarding the incidence of thromboembolic complications (deep vein thrombosis [DVT], pulmonary embolism (PE) and cerebrovascular stroke [CVS]).</offsets></p></sec><sec id="st2"><title><offsets xml_i="3348" xml_f="3369" txt_i="342" txt_f="363">Patients and Methods:</offsets></title><p><offsets xml_i="3380" xml_f="4017" txt_i="364" txt_f="1001">After obtaining institutional ethical approval 60 patients divided into three groups. Group A: Received intravenous TXA Group B: Received topical TXA Group C: Control group (placebo saline). All patients were received general anesthesia and post-operative bleeding, immediate and 24 h post-operatively, hemoglobin concentration, hematocrit, platelets and coagulation profile (prothrombin time, activated partial thromboplastin time and international normalized ratio) baseline, immediate and 24 h post-operatively. Thromboelastography was recorded baseline, immediate and 24 h post-operatively. Incidence of DVT, PE and CVS was recorded.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4048" xml_f="4056" txt_i="1003" txt_f="1011">Results:</offsets></title><p><offsets xml_i="4067" xml_f="4538" txt_i="1012" txt_f="1483">There was statistical significant elevation hemoglobin concentration and hematocrit in both Groups A and B, significant increase in blood loss in Group C, significant increase in number of patients receiving blood in Group C, there was a significant decrease in “r” and “k” times and a significant increase in maximum amplitude and α-angle in Group A, statistically significant increase in the incidence of thromboembolic events in the form of DVT, PE and CVS in Group A.</offsets></p></sec><sec id="st4"><title><offsets xml_i="4569" xml_f="4580" txt_i="1485" txt_f="1496">Conclusion:</offsets></title><p><offsets xml_i="4591" xml_f="4715" txt_i="1497" txt_f="1621">Topical TXA is effective in decreasing post-operative blood loss with possible side-effects of this route of administration.</offsets></p></sec></abstract><kwd-group><kwd>Hip arthroplasty</kwd><kwd>intravenous</kwd><kwd>topical</kwd><kwd>tranexamic acid</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="4922" xml_f="4934" txt_i="1630" txt_f="1642">INTRODUCTION</offsets></title><p><offsets xml_i="4945" xml_f="5276" txt_i="1643" txt_f="1974">Orthopedic surgery may be associated with substantial blood loss requiring transfusion of erythrocytes. Surgery for hip fractures frequently requires blood transfusion, despite recent advances in techniques of orthopedic surgery and mechanical improvements of implants. Blood may be transfused before, during or following surgery.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5309" xml_f="5310" txt_i="1974" txt_f="1975">1</offsets></xref><offsets xml_i="5317" xml_f="5318" txt_i="1975" txt_f="1976">]</offsets></p><p><offsets xml_i="5325" xml_f="5865" txt_i="1977" txt_f="2517">Surgery enhances coagulability and local fibrinolytic activity. Increases the level of coagulation factors and reduction of coagulation inhibitors together with enhanced platelets activity with the release of catecholamines contribute to hemostatis. The fibrionolytic system is activated by the surgical trauma causing the release of tissue plasminogen activators (t-PA). Furthermore, the release of t-PA triggered by thrombin activates fibrinolytic system. t-PA is the major enzyme in controlling the conversion of plasminogen to plasmin.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="5898" xml_f="5899" txt_i="2517" txt_f="2518">2</offsets></xref><offsets xml_i="5906" xml_f="5907" txt_i="2518" txt_f="2519">]</offsets></p><p><offsets xml_i="5914" xml_f="6312" txt_i="2520" txt_f="2918">The use of allogenic blood products increases the rate of transmission of infectious diseases, modulates the immune response and increases the rate of post-operative infection. Numerous methods of controlling bleeding such as thromboplastic agents; topical freezing saline; deliberate hypotension and administration of fibrinolytic inhibitors as aprotinin and tranexamic acid (TXA) have been used.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6345" xml_f="6346" txt_i="2918" txt_f="2919">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="6386" xml_f="6387" txt_i="2919" txt_f="2920">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="6427" xml_f="6428" txt_i="2920" txt_f="2921">5</offsets></xref><offsets xml_i="6435" xml_f="6436" txt_i="2921" txt_f="2922">]</offsets></p><p><offsets xml_i="6443" xml_f="6750" txt_i="2923" txt_f="3230">Meanwhile, the nature of orthopedic illness and diseases, trauma and surgical repair or replacement of hip predisposes patients to the occurrence of venous thromboembolism. These complications are predictable and are the result of alteration of the natural equilibrium mechanisms in various disease states.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="6783" xml_f="6784" txt_i="3230" txt_f="3231">6</offsets></xref><offsets xml_i="6791" xml_f="7145" txt_i="3231" txt_f="3585">] Untreated general surgical patients have a post-operative risk of deep venous thrombosis (DVT) of 19-25%. In comparison, DVT rate among high-risk orthopedic patients is substantially greater. Untreated patients following total hip replacement have a DVT rate of 50-60%. In these same series, the risk of fatal pulmonary embolism (PE) ranges 0.4-12.9%.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="7178" xml_f="7179" txt_i="3585" txt_f="3586">7</offsets></xref><xref rid="ref8" ref-type="bibr"><offsets xml_i="7219" xml_f="7220" txt_i="3586" txt_f="3587">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="7260" xml_f="7261" txt_i="3587" txt_f="3588">9</offsets></xref><offsets xml_i="7268" xml_f="7269" txt_i="3588" txt_f="3589">]</offsets></p><p><offsets xml_i="7276" xml_f="7630" txt_i="3590" txt_f="3944">TXA is a synthetic hydrophilic inhibitor of fibrinolysis. It blocks lysine binding sites of plasminogen by competitive mechanism. TXA complex are displaced from the surface of fibrin and like plasmin is prevented from binding to fibrinogen or fibrin monomers delaying lysis. With higher concentration, TXA acts as a non-competitive inhibitor of plasmin.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="7663" xml_f="7664" txt_i="3944" txt_f="3945">2</offsets></xref><offsets xml_i="7671" xml_f="7757" txt_i="3945" txt_f="4031">] However, it is contraindicated in patients with history of thromboembolic diseases.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="7791" xml_f="7793" txt_i="4031" txt_f="4033">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="7834" xml_f="7836" txt_i="4033" txt_f="4035">11</offsets></xref><offsets xml_i="7843" xml_f="7910" txt_i="4035" txt_f="4102">] Topical use of this agent is reported in coronary artery bypass.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="7944" xml_f="7946" txt_i="4102" txt_f="4104">12</offsets></xref><offsets xml_i="7953" xml_f="7954" txt_i="4104" txt_f="4105">]</offsets></p><sec id="sec2-1"><title><offsets xml_i="7982" xml_f="7998" txt_i="4106" txt_f="4122">Aim of the study</offsets></title><p><offsets xml_i="8009" xml_f="8183" txt_i="4123" txt_f="4297">The primary objective of this study was to test the effectiveness of topical TXA in reducing blood loss in pelvic hemiarthroplasty surgeries as compared with intravenous TXA.</offsets></p><p><offsets xml_i="8190" xml_f="8345" txt_i="4298" txt_f="4453">The secondary objective was to compare both techniques as regards the incidence of thromboembolic complications (DVT, PE and cerebrovascular stroke [CVS]).</offsets></p></sec></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="8404" xml_f="8424" txt_i="4456" txt_f="4476">PATIENTS AND METHODS</offsets></title><p><offsets xml_i="8435" xml_f="8879" txt_i="4477" txt_f="4921">The present study was carried out in a tertiary referral teaching hospital in a double-blind randomized placebo-controlled prospective study on 60 patients (age ranged from 50 to 60 years) undergoing hemiarthroplasty surgeries for fractured hip joint within 48 h of trauma. After obtaining approval from the ethical committee, informed consent was obtained from all patients. Patients were randomly allocated into one of the three study groups:</offsets></p><p><offsets xml_i="8886" xml_f="8887" txt_i="4922" txt_f="4923">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="8926" xml_f="8959" txt_i="4923" txt_f="4956">Group A: Received Intravenous TXA</offsets></p></list-item><list-item><p><offsets xml_i="8989" xml_f="9018" txt_i="4957" txt_f="4986">Group B: Received topical TXA</offsets></p></list-item><list-item><p><offsets xml_i="9048" xml_f="9088" txt_i="4987" txt_f="5027">Group C: Control group (placebo saline).</offsets></p></list-item></list><offsets xml_i="9111" xml_f="9112" txt_i="5028" txt_f="5029">
</offsets></p><p><offsets xml_i="9119" xml_f="9465" txt_i="5030" txt_f="5376">Patients in Group A received intravenous TXA 10 mg/kg in 20 ml normal saline as a bolus dose prior to skin incision, then by infusion of 5 mg/kg/h in the form of 500 mg TXA in 250 ml with rate of 80 ml/h until the end of surgery. Prior to wound closure 100 ml of normal saline was purred into the surgical field and left for 5 min before suction.</offsets></p><p><offsets xml_i="9472" xml_f="9775" txt_i="5377" txt_f="5680">Patients in Group B received intravenous 20 ml of normal saline before skin incision the by infusion of normal saline with a rate of 80 ml/h until the end of surgery. Prior to wound closure, 100 ml normal saline with 1.5 grams of TXA was purred into the surgical field and left for 5 min before suction.</offsets></p><p><offsets xml_i="9782" xml_f="10040" txt_i="5681" txt_f="5939">Patients in Group C received 20 ml of normal saline before skin incision then by infusion of 80 ml/h of normal saline until the end of surgery. Prior to wound closure, 100 ml of normal saline is purred in the surgical field and left for 5 min before suction.</offsets></p><p><offsets xml_i="10047" xml_f="10315" txt_i="5940" txt_f="6208">All patients of the three studied groups received prophylactic anticoagulants in the form of clexane (low molecular weight heparin) 80 international units subcutaneously within 8 h pre-operatively and were continued post-operatively according to the standard practice.</offsets></p><p><offsets xml_i="10322" xml_f="10468" txt_i="6209" txt_f="6355">All patients of the study three groups were admitted post-operatively to post-anesthesia care unit where they remained for 24 h under observation.</offsets></p><sec id="sec2-2"><title><offsets xml_i="10496" xml_f="10514" txt_i="6356" txt_f="6374">Exclusion criteria</offsets></title><p><offsets xml_i="10525" xml_f="10526" txt_i="6375" txt_f="6376">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="10565" xml_f="10579" txt_i="6376" txt_f="6390">Allergy to TXA</offsets></p></list-item><list-item><p><offsets xml_i="10609" xml_f="10646" txt_i="6391" txt_f="6428">Acquired disturbances of color vision</offsets></p></list-item><list-item><p><offsets xml_i="10676" xml_f="10766" txt_i="6429" txt_f="6513">Pre-operative anemia (hemoglobin &lt;11 gm% in females and hemoglobin &lt;12 gm% in males)</offsets></p></list-item><list-item><p><offsets xml_i="10796" xml_f="10973" txt_i="6514" txt_f="6691">Preoperative use of anticoagulant therapy i.e., oral anticoagulants, heparin within 5 days of surgery, fibrinolytic disorders requiring intraoperative antifibrinolytic treatment</offsets></p></list-item><list-item><p><offsets xml_i="11003" xml_f="11066" txt_i="6692" txt_f="6752">Coagulopathy i.e., pre-operative platelets count &lt;150,000 mm</offsets><sup><offsets xml_i="11071" xml_f="11072" txt_i="6752" txt_f="6753">3</offsets></sup><offsets xml_i="11078" xml_f="11170" txt_i="6753" txt_f="6839">, international normalized ratio (INR) &gt;1.4 and prolonged prothrombin time (PT) &gt;1.4 s</offsets></p></list-item><list-item><p><offsets xml_i="11200" xml_f="11266" txt_i="6840" txt_f="6906">A previous history of thromboembolic disease i.e.; DVT, CVS and PE</offsets></p></list-item><list-item><p><offsets xml_i="11296" xml_f="11322" txt_i="6907" txt_f="6933">Significant co-morbidities</offsets></p></list-item><list-item><p><offsets xml_i="11352" xml_f="11426" txt_i="6934" txt_f="7008">Severe ischemic heart disease, New York Heart Association Class III and IV</offsets></p></list-item><list-item><p><offsets xml_i="11456" xml_f="11486" txt_i="7009" txt_f="7039">Previous myocardial infarction</offsets></p></list-item><list-item><p><offsets xml_i="11516" xml_f="11540" txt_i="7040" txt_f="7064">Severe pulmonary disease</offsets></p></list-item><list-item><p><offsets xml_i="11570" xml_f="11656" txt_i="7065" txt_f="7151">Plasma creatinine greater than 115 mmol/L in males and more than 100 μmol/L in females</offsets></p></list-item><list-item><p><offsets xml_i="11686" xml_f="11701" txt_i="7152" txt_f="7167">Hepatic failure</offsets></p></list-item><list-item><p><offsets xml_i="11731" xml_f="11850" txt_i="7168" txt_f="7287">Occurrence Intraoperative surgical/medical/anesthetic complications i.e.; myocardial infarction or neurovascular injury</offsets></p></list-item><list-item><p><offsets xml_i="11880" xml_f="11923" txt_i="7288" txt_f="7331">Patients who need massive blood transfusion</offsets></p></list-item><list-item><p><offsets xml_i="11953" xml_f="11995" txt_i="7332" txt_f="7374">Postoperative bleeding of surgical causes.</offsets></p></list-item></list><offsets xml_i="12018" xml_f="12019" txt_i="7375" txt_f="7376">
</offsets></p></sec><sec id="sec2-3"><title><offsets xml_i="12053" xml_f="12073" txt_i="7378" txt_f="7398">Anesthetic technique</offsets></title><p><offsets xml_i="12084" xml_f="12544" txt_i="7399" txt_f="7859">Patients enrolled in the study had the same anesthetic technique: General anesthesia using propofol 1-2 mg/kg, fentanyl 1-2 microgram/kg and recuronium 0.1 mg/kg to facilitates endotracheal intubation and there after infusion using maintenance dose until the end of surgery. Sevoflurane 1-2 minimum alveolar concentration was used to maintain the anesthesia with 50% nitrous oxide in oxygen. Mechanical ventilation aiming to keep end tidal carbon dioxide (EtCo</offsets><sub><offsets xml_i="12549" xml_f="12550" txt_i="7859" txt_f="7860">2</offsets></sub><offsets xml_i="12556" xml_f="12637" txt_i="7860" txt_f="7941">) 30-35 mm Hg. Standard monitoring of Electrocardiography, pulse oximetry for SaO</offsets><sub><offsets xml_i="12642" xml_f="12643" txt_i="7941" txt_f="7942">2</offsets></sub><offsets xml_i="12649" xml_f="12904" txt_i="7942" txt_f="8197">, none invasive blood pressure, capnography for end tidal carbon dioxide, temperature and urine output. Post-operative pain was controlled using intravenous morphine titrated to the patients response. No non-steroidal analgesic anti-inflammatory was used.</offsets></p><p><offsets xml_i="12911" xml_f="13220" txt_i="8198" txt_f="8507">Intraoperative replacement therapy has been planned in this study to be on the negative balance side as over hydration may result in dilutional anemia and we also avoided the use of more than 500 cc. colloid in the replacement therapy as in a dose more than this, colloids will affect the coagulation process.</offsets></p></sec><sec id="sec2-4"><title><offsets xml_i="13254" xml_f="13271" txt_i="8509" txt_f="8526">Outcomes measured</offsets></title><p><offsets xml_i="13282" xml_f="13283" txt_i="8527" txt_f="8528">
</offsets><list list-type="order"><list-item><p><offsets xml_i="13321" xml_f="13398" txt_i="8528" txt_f="8605">Post-operative bleeding (surgical drains) immediate and 24 h post-operatively</offsets></p></list-item><list-item><p><offsets xml_i="13428" xml_f="13605" txt_i="8606" txt_f="8783">Hemoglobin concentration, hematocrite, platelets and coagulation profile (PT, activated partial thromboplastin time [APTT] and INR) baseline, immediate and 24 h post-operatively</offsets></p></list-item><list-item><p><offsets xml_i="13635" xml_f="13716" txt_i="8784" txt_f="8865">Number of patients requiring blood transfusion in the first 24 h post-operatively</offsets></p></list-item><list-item><p><offsets xml_i="13746" xml_f="14198" txt_i="8866" txt_f="9318">Thromboelastogram (TEG) was recorded baseline, immediate and 24 h post-operatively. TEG 5000 hemostasis analyzer [Haemoscope Inc. USA] was used connected to computer with the TEG analytical software, version 4.1.54. Maintenance and quality control were performed in strict accordance with manufacturers recommendations. Blood samples were collected in 1.8 ml vacutainer tubes [bection Dickinson, USA] with 3.2% sodium citrate [0.109M trisodium citrate]</offsets></p></list-item><list-item><p><offsets xml_i="14228" xml_f="14425" txt_i="9319" txt_f="9516">Incidence of DVT confirmed by symptoms and phlebography by ultrasound. PE confirmed by spiral computed tomography and CVS confirmed by computed tomographic scan or magnetic resonance imaging (MRI).</offsets></p></list-item></list><offsets xml_i="14448" xml_f="14449" txt_i="9517" txt_f="9518">
</offsets></p></sec><sec id="sec2-5"><title><offsets xml_i="14483" xml_f="14503" txt_i="9520" txt_f="9540">Statistical analysis</offsets></title><p><offsets xml_i="14514" xml_f="14777" txt_i="9541" txt_f="9804">All measurements were expressed as mean ± the standard deviation of the mean. Statistical analyses were performed with SPSS for Windows version 18.0 software (SPSS, Inc., Chicago, IL, USA). Comparisons of results between groups were carried out by the two-sample </offsets><italic><offsets xml_i="14785" xml_f="14786" txt_i="9804" txt_f="9805">t</offsets></italic><offsets xml_i="14795" xml_f="14926" txt_i="9805" txt_f="9936">-test for each normally distributed variable. For nonparametric readings Fisher Exact test was used to analyze nonparametric data. </offsets><italic><offsets xml_i="14934" xml_f="14935" txt_i="9936" txt_f="9937">P</offsets></italic><offsets xml_i="14944" xml_f="15007" txt_i="9937" txt_f="9997"> &lt; 0.05 was considered to indicate a significant difference.</offsets></p></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="15066" xml_f="15073" txt_i="10000" txt_f="10007">RESULTS</offsets></title><p><offsets xml_i="15084" xml_f="15238" txt_i="10008" txt_f="10162">Regarding demographic data (age, weight, height, male/female ratio and surgery duration), there were no significant differences among all studied groups (</offsets><italic><offsets xml_i="15246" xml_f="15247" txt_i="10162" txt_f="10163">P</offsets></italic><offsets xml_i="15256" xml_f="15269" txt_i="10163" txt_f="10173"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="15301" xml_f="15308" txt_i="10173" txt_f="10180">Table 1</offsets></xref><offsets xml_i="15315" xml_f="15317" txt_i="10180" txt_f="10182">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15365" xml_f="15372" txt_i="10183" txt_f="10190">Table 1</offsets></label><caption><p><offsets xml_i="15392" xml_f="15452" txt_i="10190" txt_f="10250">Demographic data and surgery duration for all studied groups</offsets></p></caption><graphic xlink:href="AER-8-48-g001"></graphic></table-wrap><p><offsets xml_i="15528" xml_f="15643" txt_i="10251" txt_f="10366">Concerning hematological data, there were no significant differences in the baseline values in all studied groups (</offsets><italic><offsets xml_i="15651" xml_f="15652" txt_i="10366" txt_f="10367">P</offsets></italic><offsets xml_i="15661" xml_f="15674" txt_i="10367" txt_f="10377"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="15706" xml_f="15713" txt_i="10377" txt_f="10384">Table 2</offsets></xref><offsets xml_i="15720" xml_f="15722" txt_i="10384" txt_f="10386">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="15770" xml_f="15777" txt_i="10387" txt_f="10394">Table 2</offsets></label><caption><p><offsets xml_i="15797" xml_f="15828" txt_i="10394" txt_f="10425">Hematological data during the 1</offsets><sup><offsets xml_i="15833" xml_f="15835" txt_i="10425" txt_f="10427">st</offsets></sup><offsets xml_i="15841" xml_f="15868" txt_i="10427" txt_f="10454"> 24 h in all studied groups</offsets></p></caption><graphic xlink:href="AER-8-48-g002"></graphic></table-wrap><p><offsets xml_i="15944" xml_f="16175" txt_i="10455" txt_f="10686">Values of hemoglobin and hematocrit immediate post-operatively and after 24 h showed no significant differences between Groups A and B while there was statistical significant elevation in both Groups A and B compared with Group C (</offsets><italic><offsets xml_i="16183" xml_f="16184" txt_i="10686" txt_f="10687">P</offsets></italic><offsets xml_i="16193" xml_f="16205" txt_i="10687" txt_f="10696"> &lt; 0.05).</offsets></p><p><offsets xml_i="16212" xml_f="16380" txt_i="10697" txt_f="10865">Regarding other hematological data (platelet count, PT, APTT and INR) there were no significant differences among the groups immediate and after 24 h post-operatively (</offsets><italic><offsets xml_i="16388" xml_f="16389" txt_i="10865" txt_f="10866">P</offsets></italic><offsets xml_i="16398" xml_f="16411" txt_i="10866" txt_f="10876"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="16443" xml_f="16450" txt_i="10876" txt_f="10883">Table 2</offsets></xref><offsets xml_i="16457" xml_f="16459" txt_i="10883" txt_f="10885">].</offsets></p><p><offsets xml_i="16466" xml_f="16600" txt_i="10886" txt_f="11020">Considering the mean total blood loss during the first 24 h in all groups there was no significant difference between Groups A and B (</offsets><italic><offsets xml_i="16608" xml_f="16609" txt_i="11020" txt_f="11021">P</offsets></italic><offsets xml_i="16618" xml_f="16727" txt_i="11021" txt_f="11127"> &gt; 0.05) while there was a significant increase in mean blood loss in Group C compared to Groups A and B (</offsets><italic><offsets xml_i="16735" xml_f="16736" txt_i="11127" txt_f="11128">P</offsets></italic><offsets xml_i="16745" xml_f="16758" txt_i="11128" txt_f="11138"> &lt; 0.05) [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="16790" xml_f="16797" txt_i="11138" txt_f="11145">Table 3</offsets></xref><offsets xml_i="16804" xml_f="16806" txt_i="11145" txt_f="11147">].</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="16854" xml_f="16861" txt_i="11148" txt_f="11155">Table 3</offsets></label><caption><p><offsets xml_i="16881" xml_f="16918" txt_i="11155" txt_f="11192">Blood loss (surgical drains) in the 1</offsets><sup><offsets xml_i="16923" xml_f="16925" txt_i="11192" txt_f="11194">st</offsets></sup><offsets xml_i="16931" xml_f="16936" txt_i="11194" txt_f="11199"> 24 h</offsets></p></caption><graphic xlink:href="AER-8-48-g003"></graphic></table-wrap><p><offsets xml_i="17012" xml_f="17245" txt_i="11200" txt_f="11433">Regarding the primary outcome patients receiving packed red blood cells (RBCs) during the first 24 h post-operatively we found a significant increase in number of patients receiving packed RBCs in Group C compared to Groups A and B (</offsets><italic><offsets xml_i="17253" xml_f="17254" txt_i="11433" txt_f="11434">P</offsets></italic><offsets xml_i="17263" xml_f="17276" txt_i="11434" txt_f="11444"> &lt; 0.05) [</offsets><xref ref-type="table" rid="T4"><offsets xml_i="17308" xml_f="17315" txt_i="11444" txt_f="11451">Table 4</offsets></xref><offsets xml_i="17322" xml_f="17324" txt_i="11451" txt_f="11453">].</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="17372" xml_f="17379" txt_i="11454" txt_f="11461">Table 4</offsets></label><caption><p><offsets xml_i="17399" xml_f="17454" txt_i="11461" txt_f="11516">Primary outcome patients receiving packed RBCs in the 1</offsets><sup><offsets xml_i="17459" xml_f="17461" txt_i="11516" txt_f="11518">st</offsets></sup><offsets xml_i="17467" xml_f="17472" txt_i="11518" txt_f="11523"> 24 h</offsets></p></caption><graphic xlink:href="AER-8-48-g004"></graphic></table-wrap><p><offsets xml_i="17548" xml_f="17901" txt_i="11524" txt_f="11877">As a monitor to the biomarkers of coagulopathy and maximum clot strength for detection of the effect of TXA on the coagulation and the hypercoagulable state we used the TEG. With the analysis of “r” time, “k” time, maximum amplitude (MA), α-angle and LY 30 of the thromboelastography. Baseline values showed no significant differences among all groups (</offsets><italic><offsets xml_i="17909" xml_f="17910" txt_i="11877" txt_f="11878">P</offsets></italic><offsets xml_i="17919" xml_f="17932" txt_i="11878" txt_f="11888"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="17964" xml_f="17971" txt_i="11888" txt_f="11895">Table 5</offsets></xref><offsets xml_i="17978" xml_f="17980" txt_i="11895" txt_f="11897">].</offsets></p><table-wrap id="T5" position="float"><label><offsets xml_i="18028" xml_f="18035" txt_i="11898" txt_f="11905">Table 5</offsets></label><caption><p><offsets xml_i="18055" xml_f="18096" txt_i="11905" txt_f="11946">Thromboelastography readings during the 1</offsets><sup><offsets xml_i="18101" xml_f="18103" txt_i="11946" txt_f="11948">st</offsets></sup><offsets xml_i="18109" xml_f="18137" txt_i="11948" txt_f="11976"> 24 h for all studied groups</offsets></p></caption><graphic xlink:href="AER-8-48-g005"></graphic></table-wrap><p><offsets xml_i="18213" xml_f="18399" txt_i="11977" txt_f="12163">Immediate post-operatively and after 24 h there was a significant decrease in “r” time and “k” time and a significant increase in MA and α-angle in group A compared with Groups B and C (</offsets><italic><offsets xml_i="18407" xml_f="18408" txt_i="12163" txt_f="12164">P</offsets></italic><offsets xml_i="18417" xml_f="18430" txt_i="12164" txt_f="12174"> &lt; 0.05) [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="18462" xml_f="18469" txt_i="12174" txt_f="12181">Table 5</offsets></xref><offsets xml_i="18476" xml_f="18612" txt_i="12181" txt_f="12317">]. However, there was no significant differences in LY 30 among the three groups either immediate or after first 24 h post-operatively (</offsets><italic><offsets xml_i="18620" xml_f="18621" txt_i="12317" txt_f="12318">P</offsets></italic><offsets xml_i="18630" xml_f="18643" txt_i="12318" txt_f="12328"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="18675" xml_f="18682" txt_i="12328" txt_f="12335">Table 5</offsets></xref><offsets xml_i="18689" xml_f="18691" txt_i="12335" txt_f="12337">].</offsets></p><p><offsets xml_i="18698" xml_f="19014" txt_i="12338" txt_f="12654">The main safety outcome was the incidence of thromboembolic events within 4 weeks post-operatively. These thromboembolic events were defined as the composite of DVT confirmed by symptoms and phlebography by ultrasound, PE confirmed by Spiral computed tomography and CVS confirmed by computed tomographic scan or MRI.</offsets></p><p><offsets xml_i="19021" xml_f="19430" txt_i="12655" txt_f="13064">At the end of 4 weeks interval, thromboembolic events occurred in six patients in Group A, (five patients with DVT and one patient with CVS) and in Group C, one patient with DVT. There were no thromboembolic events in any of Group B patients. There was statistically significant increase in the incidence of thromboembolic events in the form of DVT in Group A patients compared to patients in Groups B and C (</offsets><italic><offsets xml_i="19438" xml_f="19439" txt_i="13064" txt_f="13065">P</offsets></italic><offsets xml_i="19448" xml_f="19461" txt_i="13065" txt_f="13075"> &lt; 0.05) [</offsets><xref ref-type="table" rid="T6"><offsets xml_i="19493" xml_f="19500" txt_i="13075" txt_f="13082">Table 6</offsets></xref><offsets xml_i="19507" xml_f="19509" txt_i="13082" txt_f="13084">].</offsets></p><table-wrap id="T6" position="float"><label><offsets xml_i="19557" xml_f="19564" txt_i="13085" txt_f="13092">Table 6</offsets></label><caption><p><offsets xml_i="19584" xml_f="19668" txt_i="13092" txt_f="13176">Incidence of thromboembolic events (DVT, PE and CVS) within 4 weeks post-operatively</offsets></p></caption><graphic xlink:href="AER-8-48-g006"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="19793" xml_f="19803" txt_i="13178" txt_f="13188">DISCUSSION</offsets></title><p><offsets xml_i="19814" xml_f="20271" txt_i="13189" txt_f="13646">Previous studies evaluated the use of TXA intravenously to reduce perioperative bleeding and the need for blood transfusion also some researchers tested the effect of topical use of TXA on the site of surgery in favor to get its benefit of reducing blood loss and enhancing hemostasis and to avoid the hypercoagulation effect of TXA when it is used systemically. In this study, we compared the intravenous TXA to topical TXA together with the placebo group.</offsets></p><p><offsets xml_i="20278" xml_f="20564" txt_i="13647" txt_f="13933">Concerning hemoglobin and hematocrit levels, they were significantly higher in intravenous and topical TXA groups compared to placebo group. This is in agreement with studies showed that patients in TXA group also had a higher level of post-operative hemoglobin than the placebo group.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="20597" xml_f="20598" txt_i="13933" txt_f="13934">5</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="20639" xml_f="20641" txt_i="13934" txt_f="13936">13</offsets></xref><offsets xml_i="20648" xml_f="20649" txt_i="13936" txt_f="13937">]</offsets></p><p><offsets xml_i="20656" xml_f="21119" txt_i="13938" txt_f="14401">In the present study regarding the coagulation profile (PT, APTT and INR) and platelet count, there were no significant changes among pre-operative levels, immediate and 24 h post-operatively. These findings are in agreement with other studies that used TXA for blood conservation in knee arthroplasty. Their data confirmed that TXA did not induce platelet activity or platelet count and at the same time there were no significant changes on coagulation profile.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="21152" xml_f="21153" txt_i="14401" txt_f="14402">9</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="21194" xml_f="21196" txt_i="14402" txt_f="14404">13</offsets></xref><xref rid="ref14" ref-type="bibr"><offsets xml_i="21237" xml_f="21239" txt_i="14404" txt_f="14406">14</offsets></xref><offsets xml_i="21246" xml_f="21247" txt_i="14406" txt_f="14407">]</offsets></p><p><offsets xml_i="21254" xml_f="21462" txt_i="14408" txt_f="14616">Results of our study showed significant reduction of blood loss in both intravenous and topical TXA groups in comparison to the placebo group within the first post-operative 24 h. These findings go with Wong </offsets><italic><offsets xml_i="21470" xml_f="21475" txt_i="14616" txt_f="14621">et al</offsets></italic><offsets xml_i="21484" xml_f="21487" txt_i="14621" txt_f="14624">.,[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="21520" xml_f="21521" txt_i="14624" txt_f="14625">5</offsets></xref><offsets xml_i="21528" xml_f="21701" txt_i="14625" txt_f="14798">] who proved that administration of TXA significantly reduced the total perioperative blood loss in adult patients having thoracic/lumbar instrumental spinal fusion surgery.</offsets></p><p><offsets xml_i="21708" xml_f="21873" txt_i="14799" txt_f="14964">Following success of systemic use of Aprotinin and TXA in controlling post-coronary artery bypass graft (CABG) bleeding trials for topical use were started by Tatar </offsets><italic><offsets xml_i="21881" xml_f="21886" txt_i="14964" txt_f="14969">et al</offsets></italic><offsets xml_i="21895" xml_f="21898" txt_i="14969" txt_f="14972">.,[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="21931" xml_f="21932" txt_i="14972" txt_f="14973">9</offsets></xref><offsets xml_i="21939" xml_f="22108" txt_i="14973" txt_f="15142">] in 1993, who reported reduction of post-operative blood loss and the need for transfusion after topical aprotinin use in CABG. Similar results were reported by Khalil </offsets><italic><offsets xml_i="22116" xml_f="22121" txt_i="15142" txt_f="15147">et al</offsets></italic><offsets xml_i="22130" xml_f="22133" txt_i="15147" txt_f="15150">.,[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="22167" xml_f="22169" txt_i="15150" txt_f="15152">10</offsets></xref><offsets xml_i="22176" xml_f="22191" txt_i="15152" txt_f="15167">] and De Bonis </offsets><italic><offsets xml_i="22199" xml_f="22204" txt_i="15167" txt_f="15172">et al</offsets></italic><offsets xml_i="22213" xml_f="22216" txt_i="15172" txt_f="15175">.,[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="22250" xml_f="22252" txt_i="15175" txt_f="15177">11</offsets></xref><offsets xml_i="22259" xml_f="22289" txt_i="15177" txt_f="15207">] to start topical use of TXA.</offsets></p><p><offsets xml_i="22296" xml_f="22592" txt_i="15208" txt_f="15504">Our results showed that the need for packed RBCs transfusion is reduced in both intravenous and topical TXA groups in comparison to placebo group built as statistically significant. Similar findings were found that the need for blood transfusion after topical aprotinin use in CABG were reduced.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="22625" xml_f="22626" txt_i="15504" txt_f="15505">8</offsets></xref><xref rid="ref12" ref-type="bibr"><offsets xml_i="22667" xml_f="22669" txt_i="15505" txt_f="15507">12</offsets></xref><offsets xml_i="22676" xml_f="22677" txt_i="15507" txt_f="15508">]</offsets></p><p><offsets xml_i="22684" xml_f="22882" txt_i="15509" txt_f="15707">Other studies reported that the administration of TXA did not reduce the incidence of allogenic blood transfusion; However, there was tendency toward reduced amount of RBC transfusion in TXA group.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="22916" xml_f="22918" txt_i="15707" txt_f="15709">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="22959" xml_f="22961" txt_i="15709" txt_f="15711">16</offsets></xref><offsets xml_i="22968" xml_f="22969" txt_i="15711" txt_f="15712">]</offsets></p><p><offsets xml_i="22976" xml_f="23339" txt_i="15713" txt_f="16076">At the same time other studies had evaluated the use of tranexamic acid given during total knee arthroplasty decreased blood loss by 48% and significantly reduced transfusion requirements. The blood sparing effect of tranexamic acid was most evident during the first 24 hours after operation where blood loss was significantly reduced compared to control groups.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="23372" xml_f="23373" txt_i="16076" txt_f="16077">2</offsets></xref><xref rid="ref17" ref-type="bibr"><offsets xml_i="23414" xml_f="23416" txt_i="16077" txt_f="16079">17</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="23457" xml_f="23459" txt_i="16079" txt_f="16081">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="23500" xml_f="23502" txt_i="16081" txt_f="16083">19</offsets></xref><offsets xml_i="23509" xml_f="23610" txt_i="16083" txt_f="16184">] These findings are in agreement of our results regarding blood loss and need for blood transfusion.</offsets></p><p><offsets xml_i="23617" xml_f="23624" txt_i="16185" txt_f="16192">Hobson </offsets><italic><offsets xml_i="23632" xml_f="23637" txt_i="16192" txt_f="16197">et al</offsets></italic><offsets xml_i="23646" xml_f="23649" txt_i="16197" txt_f="16200">.,[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="23683" xml_f="23685" txt_i="16200" txt_f="16202">20</offsets></xref><offsets xml_i="23692" xml_f="24127" txt_i="16202" txt_f="16637">] used thromboelastogram as a monitor for coagulation in patients who received TXA during surgery. However, our study used thromboelastogram as a monitor for coagulation which showed that all parameters (significant decrease in r, k and significant increase in MA, α-Angle). These findings favor relative hypercoagulable state in intravenous TXA group in comparison to topical TXA and placebo groups and this in agreement with Mannuci </offsets><italic><offsets xml_i="24135" xml_f="24140" txt_i="16637" txt_f="16642">et al</offsets></italic><offsets xml_i="24149" xml_f="24151" txt_i="16642" txt_f="16644">.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="24185" xml_f="24187" txt_i="16644" txt_f="16646">21</offsets></xref><offsets xml_i="24194" xml_f="24263" txt_i="16646" txt_f="16715">] who reported that the use of TXA may promote hypercoagulable state.</offsets></p><p><offsets xml_i="24270" xml_f="24480" txt_i="16716" txt_f="16926">Other researchers reported that the use of TXA can decrease perioperative bleeding by attenuating the enhance fibronolytic activity that may enhance the coagulable state with the risk of thrombo embolic events[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="24513" xml_f="24514" txt_i="16926" txt_f="16927">5</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="24555" xml_f="24557" txt_i="16927" txt_f="16929">22</offsets></xref><offsets xml_i="24564" xml_f="24673" txt_i="16929" txt_f="17038">] this confirms our results by thromboelostogram, which shows hypercoagulable state in intravenous TXA group.</offsets></p><p><offsets xml_i="24680" xml_f="24953" txt_i="17039" txt_f="17312">Previous study, reported that clot stability by thrombelastography may have demonstrated evidence of increased fibrinolysis after use of tourniquet in the control group and its absence in the TXA group and this study reported incidence of hypercoagulale state in TXA group[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="24986" xml_f="24987" txt_i="17312" txt_f="17313">2</offsets></xref><offsets xml_i="24994" xml_f="25041" txt_i="17313" txt_f="17360">] which agrees with our findings in this study.</offsets></p><p><offsets xml_i="25048" xml_f="25375" txt_i="17361" txt_f="17688">As there remains a concern that TXA may promote a hypercoagulale state, our study evaluated its safety on venous and arterial outcomes. We reported 30% increased the risk of thromboembolic event in intravenous group compared to topical group which was 0% and placebo group was 5%. These findings were statistically significant.</offsets></p><p><offsets xml_i="25382" xml_f="25524" txt_i="17689" txt_f="17831">In a previous study, results showed a three-fold increased risk of vascular events with the use of intravenous TXA group compared to placebo.[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="25558" xml_f="25560" txt_i="17831" txt_f="17833">23</offsets></xref><offsets xml_i="25567" xml_f="25568" txt_i="17833" txt_f="17834">]</offsets></p><p><offsets xml_i="25575" xml_f="25737" txt_i="17835" txt_f="17997">In contrast, previous study of elective hip or knee arthroplasty, reported that use of tranexamic cid did not increase the risk of venous or arterial thrombosis.[</offsets><xref rid="ref24" ref-type="bibr"><offsets xml_i="25771" xml_f="25773" txt_i="17997" txt_f="17999">24</offsets></xref><offsets xml_i="25780" xml_f="26047" txt_i="17999" txt_f="18266">] Furthermore, in previous studies on the use of tranexamic and thrombosis failed to show any thrombogenic effect. Again these previous studies that use antifibriotylic during total knee replacement, reported no clinically relevant thromboembolic episode identified.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="26080" xml_f="26081" txt_i="18266" txt_f="18267">2</offsets></xref><xref rid="ref25" ref-type="bibr"><offsets xml_i="26122" xml_f="26124" txt_i="18267" txt_f="18269">25</offsets></xref><offsets xml_i="26131" xml_f="26132" txt_i="18269" txt_f="18270">]</offsets></p></sec><sec sec-type="conclusion" id="sec1-5"><title><offsets xml_i="26188" xml_f="26198" txt_i="18272" txt_f="18282">CONCLUSION</offsets></title><p><offsets xml_i="26209" xml_f="26383" txt_i="18283" txt_f="18457">The use of TXA either intravenous or topical during hip hemiarthroplasty reduced the post-operative blood loss and the transfusion needs during the first 24 h post-operative.</offsets></p><p><offsets xml_i="26390" xml_f="26712" txt_i="18458" txt_f="18780">However, topical use of tranexamic aicd has the adventage of more broad safety margin in thromboembolic events with lower incidence of developing thrombotic complication. So, in summary our study advised the routine use topical TXA in hip surgery with wide safety margin of complication and less risk of blood transfusion.</offsets></p><p><offsets xml_i="26719" xml_f="26835" txt_i="18781" txt_f="18897">Large comparative trials are needed for further assessment of the efficacy and safety of topical use during surgery.</offsets></p><sec id="sec2-6"><title><offsets xml_i="26863" xml_f="26888" txt_i="18898" txt_f="18923">Significance of the study</offsets></title><p><offsets xml_i="26899" xml_f="27075" txt_i="18924" txt_f="19100">The study investigated the effectiveness of Topical TXA in decreasing post-operative blood loss. It also investigated the possible side-effects of this route of administration.</offsets></p></sec></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zufferey</surname><given-names>P</given-names></name><name><surname>Merquiol</surname><given-names>F</given-names></name><name><surname>Laporte</surname><given-names>S</given-names></name><name><surname>Decousus</surname><given-names>H</given-names></name><name><surname>Mismetti</surname><given-names>P</given-names></name><name><surname>Auboyer</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?</article-title><source>Anesthesiology</source><year>2006</year><volume>105</volume><fpage>1034</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17065899</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>AJ</given-names></name><name><surname>Andreica</surname><given-names>S</given-names></name><name><surname>Claeys</surname><given-names>M</given-names></name><name><surname>D’Haese</surname><given-names>J</given-names></name><name><surname>Camu</surname><given-names>F</given-names></name><name><surname>Jochmans</surname><given-names>K</given-names></name></person-group><article-title>Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty</article-title><source>Br J Anaesth</source><year>1999</year><volume>83</volume><fpage>596</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">10673876</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannister</surname><given-names>GC</given-names></name><name><surname>Young</surname><given-names>SK</given-names></name><name><surname>Baker</surname><given-names>AS</given-names></name><name><surname>Mackinnon</surname><given-names>JG</given-names></name><name><surname>Magnusson</surname><given-names>PA</given-names></name></person-group><article-title>Control of bleeding in cemented arthroplasty</article-title><source>J Bone Joint Surg Br</source><year>1990</year><volume>72</volume><fpage>444</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2341445</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstraete</surname><given-names>M</given-names></name></person-group><article-title>Clinical application of inhibitors of fibrinolysis</article-title><source>Drugs</source><year>1985</year><volume>29</volume><fpage>236</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">2580684</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>El Beheiry</surname><given-names>H</given-names></name><name><surname>Rampersaud</surname><given-names>YR</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>H</given-names></name><name><surname>De Silva</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Tranexamic Acid reduces perioperative blood loss in adult patients having spinal fusion surgery</article-title><source>Anesth Analg</source><year>2008</year><volume>107</volume><fpage>1479</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">18931202</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Beauty</surname><given-names>JH</given-names></name></person-group><article-title>Orthopedic Knowledge</article-title><year>1999</year><publisher-loc>Rosemont, IL</publisher-loc><publisher-name>AAOS</publisher-name><fpage>63</fpage><lpage>72</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ido</surname><given-names>K</given-names></name><name><surname>Neo</surname><given-names>M</given-names></name><name><surname>Asada</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties</article-title><source>Arch Orthop Trauma Surg</source><year>2000</year><volume>120</volume><fpage>518</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11011672</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abul-Azm</surname><given-names>A</given-names></name><name><surname>Abdullah</surname><given-names>KM</given-names></name></person-group><article-title>Effect of topical tranexamic acid in open heart surgery</article-title><source>Eur J Anaesthesiol</source><year>2006</year><volume>23</volume><fpage>380</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16438759</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatar</surname><given-names>H</given-names></name><name><surname>Ciçek</surname><given-names>S</given-names></name><name><surname>Demirkiliç</surname><given-names>U</given-names></name><name><surname>Ozal</surname><given-names>E</given-names></name><name><surname>Süer</surname><given-names>H</given-names></name><name><surname>Oztürk</surname><given-names>O</given-names></name><etal></etal></person-group><article-title>Topical use of aprotinin in open heart operations</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>55</volume><fpage>659</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">7680853</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>PN</given-names></name><name><surname>Ismail</surname><given-names>M</given-names></name><name><surname>Kalmar</surname><given-names>P</given-names></name><name><surname>von Knobelsdorff</surname><given-names>G</given-names></name><name><surname>Marx</surname><given-names>G</given-names></name></person-group><article-title>Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass</article-title><source>Thromb Haemost</source><year>2004</year><volume>92</volume><fpage>568</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15351853</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bonis</surname><given-names>M</given-names></name><name><surname>Cavaliere</surname><given-names>F</given-names></name><name><surname>Alessandrini</surname><given-names>F</given-names></name><name><surname>Lapenna</surname><given-names>E</given-names></name><name><surname>Santarelli</surname><given-names>F</given-names></name><name><surname>Moscato</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Topical use of tranexamic acid in coronary artery bypass operations: A double-blind, prospective, randomized, placebo-controlled study</article-title><source>J Thorac Cardiovasc Surg</source><year>2000</year><volume>119</volume><fpage>575</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10694619</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Regan</surname><given-names>DJ</given-names></name><name><surname>Giannopoulos</surname><given-names>N</given-names></name><name><surname>Mediratta</surname><given-names>N</given-names></name><name><surname>Kendall</surname><given-names>SW</given-names></name><name><surname>Forni</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Topical aprotinin in cardiac operations</article-title><source>Ann Thorac Surg</source><year>1994</year><volume>58</volume><fpage>778</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">7524457</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camarasa</surname><given-names>MA</given-names></name><name><surname>Ollé</surname><given-names>G</given-names></name><name><surname>Serra-Prat</surname><given-names>M</given-names></name><name><surname>Martín</surname><given-names>A</given-names></name><name><surname>Sánchez</surname><given-names>M</given-names></name><name><surname>Ricós</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: A randomized clinical trial</article-title><source>Br J Anaesth</source><year>2006</year><volume>96</volume><fpage>576</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16531440</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Birkmeyer</surname><given-names>NJ</given-names></name><name><surname>O’Connor</surname><given-names>GT</given-names></name></person-group><article-title>Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>2801</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17533182</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethna</surname><given-names>NF</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name><name><surname>Brustowicz</surname><given-names>RM</given-names></name><name><surname>Bacsik</surname><given-names>J</given-names></name><name><surname>Sullivan</surname><given-names>LJ</given-names></name><name><surname>Shapiro</surname><given-names>F</given-names></name></person-group><article-title>Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery</article-title><source>Anesthesiology</source><year>2005</year><volume>102</volume><fpage>727</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15791100</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><article-title>American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies</article-title><source>Anesthesiology</source><year>2006</year><volume>105</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">16810012</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrishami</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><article-title>Topical application of antifibrinolytic drugs for on-pump cardiac surgery: A systematic review and meta-analysis</article-title><source>Can J Anaesth</source><year>2009</year><volume>56</volume><fpage>202</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19247741</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasim</surname><given-names>A</given-names></name><name><surname>Aşik</surname><given-names>R</given-names></name><name><surname>Atahan</surname><given-names>E</given-names></name></person-group><article-title>Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery</article-title><source>Anadolu Kardiyol Derg</source><year>2005</year><volume>5</volume><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15755701</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Good</surname><given-names>L</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Lisander</surname><given-names>B</given-names></name></person-group><article-title>Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement</article-title><source>Br J Anaesth</source><year>2003</year><volume>90</volume><fpage>596</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">12697586</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>AR</given-names></name><name><surname>Agarwala</surname><given-names>RA</given-names></name><name><surname>Swallow</surname><given-names>RA</given-names></name><name><surname>Dawkins</surname><given-names>KD</given-names></name><name><surname>Curzen</surname><given-names>NP</given-names></name></person-group><article-title>Thrombelastography: Current clinical applications and its potential role in interventional cardiology</article-title><source>Platelets</source><year>2006</year><volume>17</volume><fpage>509</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">17127479</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannucci</surname><given-names>PM</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name></person-group><article-title>Prevention and treatment of major blood loss</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>2301</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">17538089</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperzel</surname><given-names>M</given-names></name><name><surname>Huetter</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of aprotinin and tranexamic acid in different <italic>in vitro</italic>and <italic>in vivo</italic>models of fibrinolysis, coagulation and thrombus formation</article-title><source>J Thromb Haemost</source><year>2007</year><volume>5</volume><fpage>2113</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17666018</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zufferey</surname><given-names>PJ</given-names></name><name><surname>Miquet</surname><given-names>M</given-names></name><name><surname>Quenet</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Adam</surname><given-names>P</given-names></name><name><surname>Albaladejo</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Tranexamic acid in hip fracture surgery: A randomized controlled trial</article-title><source>Br J Anaesth</source><year>2010</year><volume>104</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19926634</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>KM</given-names></name><name><surname>Ismail</surname><given-names>H</given-names></name></person-group><article-title>Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: A meta-analysis</article-title><source>Anaesth Intensive Care</source><year>2003</year><volume>31</volume><fpage>529</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">14601276</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benoni</surname><given-names>G</given-names></name><name><surname>Fredin</surname><given-names>H</given-names></name></person-group><article-title>Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: A prospective, randomised, double-blind study of 86 patients</article-title><source>J Bone Joint Surg Br</source><year>1996</year><volume>78</volume><fpage>434</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8636182</pub-id></element-citation></ref></ref-list></back></article>